FDA Clears AI-Powered Device for Detecting Skin Cancer

Medical device manufacturer DermaSensor announced this week that the US Food and Drug Administration (FDA) has cleared its handheld artificial intelligence (AI)-based device, which is also called the DermaSensor, for the detection of skin cancer.

Skin cancer, the most common cancer in the world, is typically identified using dermatoscopy, a procedure in which a medical professional examines the skin for abnormalities associated with skin cancer using a specialized magnifying glass or through a visual examination.

The DermaSensor uses light in concert with an AI-powered algorithm to help physicians identify the presence of cancer in suspicious moles and lesions.

The FDA clearance is based on the findings of a study that demonstrated the DermaSensor showed a 96% sensitivity in detecting skin cancers, while a negative test result had a 97% chance of being benign, according to the company.